Literature DB >> 15797041

Impact of large tumor size on survival after resection of pathologically node negative (pN0) non-small cell lung cancer.

Shin-ichi Takeda1, Shimao Fukai, Hikotaro Komatsu, Etsuo Nemoto, Kenji Nakamura, Masaru Murakami.   

Abstract

BACKGROUND: The current TNM staging system first adopted the tumor size of 3 cm for subdivision of stage I and II disease. The aim of the present study was to evaluate the impact of tumor size on survival in patients with pathologically node negative (pN0) non-small cell lung cancer after complete resection.
METHODS: We retrospectively reviewed the records of 603 patients with pN0 non-small cell lung cancer patients (403 men and 200 women) who underwent a complete resection in five national chest hospitals between 1992 and 1996, with follow-up duration of more than 5 years, and analyzed tumor size and survival. Survival rate was estimated by the Kaplan-Meier method, and differences were compared by log-rank test. For the multivariate analysis, the Cox proportional hazard model was used to identify variables that significantly affected survival.
RESULTS: There were 355 adenocarcinomas, 208 squamous cell carcinomas, and 40 large cell carcinomas completely resected. No significant prognostic differences were seen among three groups with smaller-sized tumors (< or =2 cm [n = 171], 2.1 to 3 cm [n = 202], and 3.1 to 5 cm [n = 170]); however, patients with a tumor size greater than 5 cm (n = 60) showed a significantly worse prognosis. The 5-year survival rates were 79.6%, 72.7%, 68.1%, and 46.6%, respectively, in these four groups. Multivariate analysis showed the tumor size to be an independent prognostic predictor in patients with pN0 tumors.
CONCLUSIONS: We found that a tumor size of greater than 5 cm was an independent prognostic predictor in pN0 disease; therefore, upgrading the T factor of tumor diameter to greater than 5 cm may be necessary in the next reversion of the TNM staging system.

Entities:  

Mesh:

Year:  2005        PMID: 15797041     DOI: 10.1016/j.athoracsur.2004.09.062

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Use of 18F-FDG PET/CT to predict short-term outcomes early in the course of chemoradiotherapy in stage III adenocarcinoma of the lung.

Authors:  Xiang-Rong Zhao; Yong Zhang; Yong-Hua Yu
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

2.  Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.

Authors:  Jianjun Zhang; Kathryn A Gold; Heather Y Lin; Stephen G Swisher; Yan Xing; J Jack Lee; Edward S Kim; William N William
Journal:  J Thorac Oncol       Date:  2015-04       Impact factor: 15.609

Review 3.  Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria.

Authors:  Andrea Caulo; Saeed Mirsadraee; Fabio Maggi; Lucia Leccisotti; Edwin J R van Beek; Lorenzo Bonomo
Journal:  Eur Radiol       Date:  2011-10-04       Impact factor: 5.315

4.  Initial clinical experience with stereotactic lung radiotherapy, based on a biological model-driven prescription method.

Authors:  C Wesley Hodge; Wolfgang A Tomé; Tracy Weigel; Anne M Traynor; Minesh P Mehta
Journal:  J Radiosurg SBRT       Date:  2011

5.  Clinical analysis of stereotactic body radiation therapy using extracranial gamma knife for patients with mainly bulky inoperable early stage non-small cell lung carcinoma.

Authors:  Dajun Wu; Hong Zhu; Hanjun Tang; Changlin Li; Feng Xu
Journal:  Radiat Oncol       Date:  2011-07-20       Impact factor: 3.481

6.  Nomogram for Predicting the Relationship between the Extent of Visceral Pleural Invasion and Survival in Non-Small-Cell Lung Cancer.

Authors:  Fan Wang; Pei Li; Fengsen Li
Journal:  Can Respir J       Date:  2021-05-24       Impact factor: 2.409

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.